Bli medlem
Bli medlem

Du är här

2015-11-06

Senzime: Improved patient monitoring is rewarded - Senzimes subsidiary company MD Biomedical "The Year's Spin-Off Company" of the Umeå Gala

Uppsala, November 5, 2015. Senzimes (publ) subsidiary MD Biomedical AB
became the year's spin-off company of the Umeå Gala. To win the
award, a company must have its basis in research/education at Umeå
University, SLU or industrial research in Umeå. The company should
have a strong business growth and clear mission. Umeå Gala is an
annually event attracting over eight hundred participants from across
the region.

MD Biomedical AB originates from Umeå University where Pernilla
Abrahamsson, during her postgraduate studies, discovered the
possibility of measuring metabolic changes from the surface of an
organ instead of penetrating the organ with a needle. MD Biomedical
AB has developed and patented OnZurf Probe suited for measurements on
the surface of various organs. The discovery means less risk of
complications and thus expands the use of microdialysis technique.

The idea came by chance when Pernilla Abrahamsson placed a
conventional probe inside the heart muscle. Accidentally the probe
slipped out of the heart and ended up on the surface without a
difference in the readings and so the idea was born to develop a
"milder" probe that could be placed on the surface instead of being
inserted into the organ.

"Onzurf Probe can improve the quality of life for seriously ill
patients while reducing the number of long hospital stays and become
a cost effective solution for the county councils. To receive the
award as a spin-off is a great honor and recognition prior the
challenging and exciting commercialization phase ", says Pernilla
Abrahamsson, product and business development manager at Senzime AB.

For further information, please contact:
Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com

Pernilla Abrahamsson, product and business development manager Senzime
AB

Tel: +46 70-37 37 472, e-post: pernilla.abrahamsson@senzime.com
About Senzime

Senzime develops and markets analytical instruments and related
disposable products, enabling automated, continuous monitoring of
vital substances including glucose (sugar), in biological fluids.
Senzime has two platforms for continuously monitoring glucose and
lactate - BioSenz in biotech environment and CliniSenz for continuous
patient-monitoring. Via microdialysis in tissue or blood Senzime
offers a complete system enabling continuous monitoring which is
critical to detect post- surgery complications. The company's share
is listed on Aktietorget since 2008. www.senzime.com

About OnZurf

OnZurf, a new generation of microdialysis catheters that allow for
organ specific monitoring of, for example, bowel, liver and heart
after surgery. Microdialysis is a technology that was originally
developed at the Karolinska Institute in the 1970's and is today
validated in over 15,000 scientific studies.

-----------------------------------------------------------
http://news.cision.com/senzime/r/improved-patient-monitoring-is-rewarded...
http://mb.cision.com/Main/11572/9862271/441052.pdf

Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.